Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.76
ARRY's Cash to Debt is ranked lower than
73% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. ARRY: 1.76 )
Ranked among companies with meaningful Cash to Debt only.
ARRY' s 10-Year Cash to Debt Range
Min: 0.49  Med: 4.94 Max: No Debt
Current: 1.76
Equity to Asset 0.24
ARRY's Equity to Asset is ranked lower than
88% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ARRY: 0.24 )
Ranked among companies with meaningful Equity to Asset only.
ARRY' s 10-Year Equity to Asset Range
Min: -1.55  Med: 0.35 Max: 0.93
Current: 0.24
-1.55
0.93
F-Score: 4
Z-Score: -0.45
M-Score: -6.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -5.45
ARRY's Operating margin (%) is ranked higher than
65% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. ARRY: -5.45 )
Ranked among companies with meaningful Operating margin (%) only.
ARRY' s 10-Year Operating margin (%) Range
Min: -410.11  Med: -75.50 Max: -12.98
Current: -5.45
-410.11
-12.98
Net-margin (%) -13.45
ARRY's Net-margin (%) is ranked higher than
61% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. ARRY: -13.45 )
Ranked among companies with meaningful Net-margin (%) only.
ARRY' s 10-Year Net-margin (%) Range
Min: -511.63  Med: -83.19 Max: -12.77
Current: -13.45
-511.63
-12.77
ROA (%) -3.92
ARRY's ROA (%) is ranked higher than
69% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. ARRY: -3.92 )
Ranked among companies with meaningful ROA (%) only.
ARRY' s 10-Year ROA (%) Range
Min: -99.03  Med: -40.01 Max: -5.01
Current: -3.92
-99.03
-5.01
ROC (Joel Greenblatt) (%) 50.49
ARRY's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. ARRY: 50.49 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ARRY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -829.85  Med: -147.71 Max: -22.42
Current: 50.49
-829.85
-22.42
Revenue Growth (3Y)(%) -36.00
ARRY's Revenue Growth (3Y)(%) is ranked lower than
78% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ARRY: -36.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ARRY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -36  Med: -2.70 Max: 39.4
Current: -36
-36
39.4
EBITDA Growth (3Y)(%) -1.10
ARRY's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. ARRY: -1.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ARRY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -65.7  Med: -1.10 Max: 101.4
Current: -1.1
-65.7
101.4
EPS Growth (3Y)(%) -12.20
ARRY's EPS Growth (3Y)(%) is ranked lower than
54% of the 417 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. ARRY: -12.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ARRY' s 10-Year EPS Growth (3Y)(%) Range
Min: -50.5  Med: -2.80 Max: 55.7
Current: -12.2
-50.5
55.7
» ARRY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ARRY Guru Trades in Q1 2014

Jim Simons Sold Out
» More
Q3 2014

ARRY Guru Trades in Q3 2014

Jim Simons 14,852 sh (New)
Steven Cohen 1,425,300 sh (New)
» More
Q4 2014

ARRY Guru Trades in Q4 2014

Jim Simons Sold Out
Steven Cohen 903,300 sh (-36.62%)
» More
Q1 2015

ARRY Guru Trades in Q1 2015

Jim Simons 1,054,652 sh (New)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ARRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 15.85
ARRY's P/B is ranked lower than
88% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. ARRY: 15.85 )
Ranked among companies with meaningful P/B only.
ARRY' s 10-Year P/B Range
Min: 2.24  Med: 5.13 Max: 50.06
Current: 15.85
2.24
50.06
P/S 16.79
ARRY's P/S is ranked lower than
59% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. ARRY: 16.79 )
Ranked among companies with meaningful P/S only.
ARRY' s 10-Year P/S Range
Min: 1.43  Med: 6.51 Max: 23.97
Current: 16.79
1.43
23.97
EV-to-EBIT 182.35
ARRY's EV-to-EBIT is ranked lower than
90% of the 227 Companies
in the Global Biotechnology industry.

( Industry Median: 32.48 vs. ARRY: 182.35 )
Ranked among companies with meaningful EV-to-EBIT only.
ARRY' s 10-Year EV-to-EBIT Range
Min: -511.9  Med: -6.50 Max: -1.2
Current: 182.35
-511.9
-1.2
Current Ratio 4.38
ARRY's Current Ratio is ranked higher than
50% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. ARRY: 4.38 )
Ranked among companies with meaningful Current Ratio only.
ARRY' s 10-Year Current Ratio Range
Min: 0.81  Med: 2.65 Max: 7.86
Current: 4.38
0.81
7.86
Quick Ratio 4.38
ARRY's Quick Ratio is ranked higher than
52% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. ARRY: 4.38 )
Ranked among companies with meaningful Quick Ratio only.
ARRY' s 10-Year Quick Ratio Range
Min: 0.81  Med: 2.65 Max: 7.55
Current: 4.38
0.81
7.55
Days Sales Outstanding 16.94
ARRY's Days Sales Outstanding is ranked higher than
86% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 60.21 vs. ARRY: 16.94 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARRY' s 10-Year Days Sales Outstanding Range
Min: 2.06  Med: 19.06 Max: 497.21
Current: 16.94
2.06
497.21

Valuation & Return

vs
industry
vs
history
Price/Net Cash 24.74
ARRY's Price/Net Cash is ranked lower than
81% of the 428 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. ARRY: 24.74 )
Ranked among companies with meaningful Price/Net Cash only.
ARRY' s 10-Year Price/Net Cash Range
Min: 2.76  Med: 7.09 Max: 141.11
Current: 24.74
2.76
141.11
Price/Net Current Asset Value 21.07
ARRY's Price/Net Current Asset Value is ranked lower than
82% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. ARRY: 21.07 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ARRY' s 10-Year Price/Net Current Asset Value Range
Min: 2.24  Med: 5.40 Max: 48.85
Current: 21.07
2.24
48.85
Price/Tangible Book 15.81
ARRY's Price/Tangible Book is ranked lower than
84% of the 688 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. ARRY: 15.81 )
Ranked among companies with meaningful Price/Tangible Book only.
ARRY' s 10-Year Price/Tangible Book Range
Min: 1.14  Med: 3.79 Max: 45.18
Current: 15.81
1.14
45.18
Price/Median PS Value 2.57
ARRY's Price/Median PS Value is ranked lower than
82% of the 505 Companies
in the Global Biotechnology industry.

( Industry Median: 1.14 vs. ARRY: 2.57 )
Ranked among companies with meaningful Price/Median PS Value only.
ARRY' s 10-Year Price/Median PS Value Range
Min: 0.22  Med: 0.96 Max: 3.33
Current: 2.57
0.22
3.33
Earnings Yield (Greenblatt) (%) 0.50
ARRY's Earnings Yield (Greenblatt) (%) is ranked higher than
75% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. ARRY: 0.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ARRY' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0  Med: 0.70 Max: 0.8
Current: 0.5
0
0.8

Analyst Estimate

Jun15 Jun16
EPS($) -0.56 -0.26
EPS without NRI($) -0.56 -0.26

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AR2.Germany,
Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. The Company's proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways. In addition, pharmaceutical and biotechnology companies partner with the Company to discover and develop drug candidates across various therapeutic areas. The Company is evolving into a late-stage development company, with two wholly-owned programs, ARRY-614 and ARRY-520, and three partnered programs, selumetinib partnered with AstraZeneca, MEK162 partnered with Novartis, and danoprevir, an NS3 protease inhibitor, partnered with InterMune / Roche, having the potential to begin pivotal trials by the end of calendar year 2013. The Company's proprietary clinical programs include ARRY-520, ARRY-614, ARRY-797, and ARRY-502. The Company's internal drug discovery programs include inhibitors that target Trk receptors for the treatment of pain and G-protein-coupled receptor 119 for the treatment of diabetes. The Company competes with companies worldwide that are engaged in the research and discovery, licensing, development and commercialization of drug candidates, including large pharmaceutical companies with internal discovery and development functions, biotech companies with competing products in the therapeutic areas it is targeting and contract research organizations that perform many of the functions it performs under its collaborations. The Company is subject to substantial regulation by governmental agencies in the U.S. and other countries.
» More Articles for ARRY

Headlines

Articles On GuruFocus.com
Novartis Gets FTC Nod To Buyout Glaxo Smithkline’s Cancer Drugs Feb 25 2015 
Can These Three BioTech Companies Make It Big? Feb 20 2015 
comment on ARRY Mar 02 2013 
Re: ARRY Aug 29 2011 
Drug Penny Stock Aug 23 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,310 Shares Mar 16 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,403 Shares Feb 11 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,272 Shares Jan 13 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,256 Shares Dec 10 2010 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,220 Shares Nov 12 2010 

More From Other Websites
Array Biopharma Inc Earnings Call scheduled for 9:00 am ET today Aug 03 2015
Array BioPharma reports 4Q loss Aug 03 2015
Array BioPharma reports 4Q loss Aug 03 2015
Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 Aug 03 2015
8:04 am Array Biopharma beats by $0.07, beats on revs; provides clinical update Aug 03 2015
Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 Aug 03 2015
Q4 2015 Array Biopharma Inc Earnings Release - Before Market Open Aug 03 2015
Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 On... Jul 27 2015
Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 On... Jul 27 2015
ARRAY BIOPHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 22 2015
AstraZeneca Provides Update On Selumetinib In Uveal Melanoma Jul 22 2015
Array BioPharma To Present At The Cantor Fitzgerald 2015 Healthcare Conference Jul 06 2015
Array BioPharma To Present At The Cantor Fitzgerald 2015 Healthcare Conference Jul 06 2015
Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer... Jul 06 2015
ARRAY BIOPHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 06 2015
Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer... Jul 06 2015
One Of Mark Lampert’s Small-Cap Biotech Picks Has Returned 84% This Year And It’s Not Done Yet Jun 10 2015
Redmile Group returns an estimated 9.3% in May Jun 04 2015
ARRAY BIOPHARMA INC Files SEC form 8-K, Entry into a Material Definitive Agreement Jun 02 2015
Binimetinib And Encorafenib Combination Shows Promising Clinical Activity And Potential... Jun 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK